Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor

Ursula Matulonis • 20 May 2020
ASCO 2020
Ovarian Cancer

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Matulonis

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
6:40
KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
Ursula Matulonis • 20 May 2020
Looking forward to ASCO: updates in ovarian cancer
3:47
Looking forward to ASCO: updates in ovarian cancer
Ursula Matulonis • 20 May 2020
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
3:10
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Ursula Matulonis • 7 Oct 2016
Introduction to KEYNOTE-100 trial of pembrolizumab in advanced recurrent ovarian cancer
1:15
Introduction to KEYNOTE-100 trial of pembrolizumab in advanced recurrent ovarian cancer
Ursula Matulonis • 7 Oct 2016

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals